BioNTech had a strong quarter despite slowing COVID sales. A robust pipeline makes it a takeover target for larger pharma companies. A share repurchase program should help support price action in 2023. 5 stocks we like better than BioNTech BioNTech (NASDAQ:BNTX) got a substantial boost from the pandemic and its mRNA vaccine, developed with Pfizer […]